The pulvinar is no ordinary relay. While early textbook accounts cast the thalamus as a simple switching station funneling sensory signals to the cortex, the pulvinar sits at the top of the hierarchy as a higher-order hub, coordinating communication between distant cortical networks. It is densely interconnected with visual, attentional, and association cortices, and it has been implicated in attentional filtering, visual salience assignment, and the integration of information across brain-wide networks. Because cortico-cortical pathways in schizophrenia have repeatedly shown disruption in imaging studies, and because the pulvinar orchestrates precisely such long-range coordination, the research team led by Yuanjun Xie and Qiang Hu reasoned that individualized deviations in pulvinar-cortical connectivity might carry a signature of clinical heterogeneity that conventional group-average analyses wash out.

To test that idea, the team assembled resting-state functional MRI data from 746 healthy controls and 387 patients with schizophrenia drawn from multiple scanning sites—a scale that matters, because site-specific differences in scanners and protocols can masquerade as biological signals if not carefully handled. Rather than comparing patients to controls as groups, the researchers built a normative model from the healthy reference data. Normative modeling is a technique borrowed in spirit from growth charts in pediatrics: instead of asking whether a group differs on average, it estimates, for each individual, how far that person’s brain features deviate from the expected range given the healthy population. Each patient thus received an individualized deviation profile describing where and how strongly their pulvinar-cortical functional connections strayed from the norm.

The next challenge was dimensional reduction guided by clinical relevance. Raw connectivity deviation maps contain thousands of features, far too many to cluster meaningfully without the solution being dominated by noise. The team therefore applied a symptom-guided feature selection strategy, retaining the connections whose deviations tracked symptom measures, and then ran unsupervised clustering within this clinically enriched, low-dimensional feature space. Unsupervised clustering is deliberately blind to diagnosis labels; it simply asks whether patients fall into natural subgroups based on their brain deviation patterns. The answer was yes: two partially separable biotypes emerged, and critically, they were not arbitrary mathematical artifacts but carried clinical meaning.

That meaning was anchored most strongly in negative symptom severity. The two biotypes differed significantly on this clinical dimension, and the difference survived statistical adjustment for scanning site and other available covariates—a crucial robustness check in multisite psychiatry research, where demographic and technical confounds can easily manufacture spurious subgroups. In other words, the brain-based split corresponded to a real, measurable difference in how ill patients were in the negative-symptom domain, the domain that most strongly predicts long-term functional outcome and that has proven most resistant to existing antipsychotic medications.

Where in the brain did the symptom-relevant deviations live? The connections that drove the biotype separation showed a structured cortical distribution, concentrated predominantly in the somatomotor, visual, and ventral attention networks. This distribution is intriguing on several counts. The somatomotor network’s involvement resonates with the well-documented motor abnormalities in psychosis, including soft neurological signs and psychomotor slowing that often precede overt illness. The visual network’s prominence fits with the pulvinar’s role as the principal higher-order nucleus of the visual system, and the ventral attention network’s contribution aligns with the salience-processing disturbances long proposed to underlie psychotic experience. Together, the pattern suggests that schizophrenia’s heterogeneity is written, at least in part, into how the pulvinar dialogues with specific cortical systems rather than being a diffuse, nonspecific connectivity decline.

To add molecular context to the circuit-level findings, the team performed imaging-transcriptomic analyses, which link spatial patterns of brain deviation to the spatial expression maps of genes across the cortex. These analyses were explicitly exploratory, but they yielded coherent profiles. Biotype 1 was associated with enrichment of biological processes involving translation, protein targeting, and synaptic organization—pathways pointing toward the machinery that builds and maintains synapses. Biotype 2 showed a distinct profile involving neurodevelopment, synaptic remodeling, and metal-ion homeostasis, hinting at altered developmental and plasticity programs and at the regulation of ions such as zinc and copper that shape synaptic function. The two molecular fingerprints, like the two connectivity patterns, were related but distinguishable, consistent with the notion of partially separable biologies under one diagnostic umbrella.

The researchers also stress-tested their solution. Site-exclusion analyses, in which the clustering was repeated while leaving out individual scanning sites, indicated that the biotype solution was partially stable, although the degree of clinical separation varied from site to site. That variation is an honest caveat: it signals that while the framework captures something real, its sensitivity is not yet uniform across acquisition environments, and multisite harmonization remains a live challenge for connectomic psychiatry.

Perhaps the most clinically provocative—and most cautiously framed—result came from a projection into an independent cohort of patients receiving repetitive transcranial magnetic stimulation, a noninvasive brain stimulation treatment sometimes used for resistant symptoms. When the biotype assignments derived from the pulvinar-cortical deviation framework were applied to this treatment cohort, the researchers observed nominal, uncorrected differences in negative symptom improvement at two weeks between biotypes. However, those differences were not sustained at the four-week follow-up, and the authors are explicit that the finding should be considered hypothesis-generating rather than evidence that the biotypes predict treatment response. Still, the exercise sketches a tantalizing path forward: if brain-defined subgroups could eventually be shown to respond differently to specific interventions, biotyping could move from descriptive science toward personalized treatment selection.

The study’s authors are careful about what their work does and does not establish. The findings support a symptom-guided, pulvinar-centered framework for characterizing schizophrenia’s heterogeneity, but independent replication using prespecified models is required before the biotypes can be considered clinically or biologically valid. That caution is warranted in a field where data-driven subtyping has a history of solutions that fail to travel across datasets. Yet the combination of a large sample, an individualized normative approach, clinical anchoring, covariate-adjusted robustness, molecular context, and a treatment-cohort projection represents an unusually complete methodological pipeline. If the two pulvinar-cortical biotypes hold up under independent replication, clinicians may one day supplement a symptom-based diagnosis with a circuit-based one—distinguishing, at the level of thalamocortical wiring, the different illnesses that today share a single name.

Subject of Research: Pulvinar-cortical functional connectivity deviations defining symptom-relevant schizophrenia biotypes

Article Title: Pulvinar-cortical connectomic deviations identify symptom-relevant biotypes in schizophrenia

Article References: Xie, Y., Liu, W., Guan, M., Yang, R., Wu, D., Ma, H., Wang, Z., & Hu, Q. (2026). Pulvinar-cortical connectomic deviations identify symptom-relevant biotypes in schizophrenia. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04495-4

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04495-4

Keywords: schizophrenia, pulvinar, thalamus, connectomics, normative modeling, resting-state fMRI, negative symptoms, biotypes, imaging transcriptomics, transcranial magnetic stimulation, brain networks, psychiatry

The research, led by Xueping Wang, Zhewei Kang and colleagues under the corresponding authorship of Weihua Yue, took an exploratory but systematic approach. Rather than asking which genes contribute to schizophrenia risk in general, the team asked a pharmacogenomic question: which genetic differences predict how well negative symptoms respond to medication? They focused on two atypical antipsychotics, aripiprazole and ziprasidone, and tracked patients over a six-week course of monotherapy, meaning each participant received only one of the two drugs, without other antipsychotic medications complicating the picture.

The clinical yardstick in the study was the Positive and Negative Syndrome Scale, or PANSS, one of the most widely used instruments in schizophrenia research. The PANSS breaks a patient’s symptoms into positive items, such as hallucinations and suspiciousness, and negative items, such as emotional blunting and avolition. The researchers measured the reduction in the PANSS negative subscale score, abbreviated PANSS-N, after six weeks of treatment. A large drop in this score signals meaningful recovery of motivation, expressiveness and social engagement — the domains that most strongly determine long-term functional prognosis.

To find genetic predictors of that recovery, the team performed a genome-wide association study, or GWAS, in Han Chinese patients with schizophrenia. A GWAS scans hundreds of thousands of genetic positions across the genome, looking for variants — single-letter differences in DNA called single nucleotide polymorphisms — that statistically track with the trait of interest. In this case, the trait was the degree of PANSS-N reduction. The scan produced a standout result: a variant known as rs28502452 in the MCTP2 gene showed an association with negative symptom improvement, reaching a significance level of P = 8.01 × 10⁻⁶. In the language of statistics, this means the probability of seeing such an association by chance alone is roughly eight in a million — not genome-wide definitive on its own, but a striking signal for an exploratory analysis.

MCTP2 is not a random stretch of DNA. The gene encodes multiple C2 domain-containing transmembrane proteins, molecular scaffolds found at synapses, the junctions where neurons communicate with one another. C2 domains are calcium-binding modules, which immediately hints at the gene’s functional territory: calcium is the universal trigger for neurotransmitter release, and synaptic calcium signaling is central to learning, memory and perception. Previous work has implicated MCTP2 in higher cognitive functions, and the gene has drawn particular attention for its role in facial recognition — the ability to identify individuals and read expressions from faces, a skill that depends on a specialized network of brain regions and one that is often impaired in neurodevelopmental and neurodegenerative conditions.

The association became more compelling when the researchers layered expression data on top of the genetic result. Using expression quantitative trait loci, or eQTL, analysis — a technique that links DNA variants to the activity level of nearby or distant genes — they determined that the alleles associated with greater PANSS-N reduction were the same alleles linked to higher MCTP2 expression. In other words, patients whose genomes drive stronger production of the MCTP2 protein responded better to treatment on the negative symptom dimension. This directionality matters, because it suggests a biologically coherent story rather than a statistical fluke: more MCTP2, better cognitive and emotional function, greater improvement when the synaptic chemistry is adjusted by medication.

To test whether MCTP2’s role extends beyond schizophrenia, the team examined gene expression patterns in three disorders: schizophrenia, Alzheimer’s disease and autism spectrum disorder. Across all three, the analyses supported a positive regulatory role for MCTP2 in normal cognitive function — that is, wherever MCTP2 activity is diminished, cognition tends to suffer, and the gene’s expression profile behaves as a guardian of cognitive health rather than a disease driver. This cross-disorder consistency is notable because schizophrenia, Alzheimer’s and autism are very different conditions, yet all three involve disruptions of synaptic function and higher cognition, and all three may converge on the same molecular machinery.

The researchers then mapped the protein interaction landscape around MCTP2. Protein–protein interaction networks chart which gene products physically or functionally cooperate inside cells, and the analysis revealed a tightly connected cluster centered on calcium signaling, featuring the genes SLITRK5, NCALD and CPNE5. SLITRK5 is a synaptic protein known to shape dendritic growth and excitatory synapse development; NCALD, or neurocalcin delta, is a calcium sensor expressed in neurons; CPNE5, a copine family member, is also calcium-dependent. The cluster’s identity dovetailed with the network pharmacology analysis, a computational method that maps the molecular targets of a drug across cellular pathways. For both aripiprazole and ziprasidone, the calcium signaling pathway emerged as a major component of the drugs’ pharmacological networks — meaning the very pathway housing MCTP2’s interaction partners is one that the two medications themselves engage.

Perhaps the most intriguing structural finding concerns two synaptic proteins, SLITRK5 and PTPRD, which the analysis suggests may regulate the interaction network connecting MCTP2 with another gene, BTBD9. Both MCTP2 and BTBD9 are described in the study as high-risk genes for the improvement of negative symptoms, and the possibility that SLITRK5 and PTPRD act as intermediaries — molecular brokers wiring MCTP2 and BTBD9 into a shared circuit — offers a concrete hypothesis for how genetic variation at multiple loci could converge on a single functional outcome: the recovery of motivation, affect and social engagement under antipsychotic treatment.

The authors are careful to frame the work as exploratory, and the association signal, while strong for a first pass, will need replication in independent cohorts before it can inform clinical practice. The study population was exclusively Han Chinese, and pharmacogenomic associations can differ across ancestries, so international replication is an obvious next step. Nevertheless, the findings sketch a foundation for three intertwined research agendas: understanding the biology of negative symptoms, which remain the least treatable facet of schizophrenia; dissecting the genetics of cognitive impairment across psychiatric and neurodegenerative disease; and developing targeted therapies that could one day be matched to a patient’s genotype. If the MCTP2-centered calcium signaling network holds up under scrutiny, it could shift the field’s attention toward a mechanistic axis that connects synaptic calcium dynamics, social cognition and drug response — and toward a future in which a simple genetic test helps clinicians predict, before the first prescription is written, which patients are most likely to reclaim the motivation and emotional warmth that schizophrenia so often takes away.

Subject of Research: Genetic and expression analysis of MCTP2 in relation to negative symptom improvement in schizophrenia patients treated with antipsychotics

Article Title: Exploratory genetic and expression analysis identifies MCTP2 associated with negative symptom improvement in schizophrenia

Article References: Wang, X., Kang, Z., Zhang, Y., Sun, Y., Lu, T., Yan, H., & Yue, W. (2026). Exploratory genetic and expression analysis identifies MCTP2 associated with negative symptom improvement in schizophrenia. Schizophrenia. https://doi.org/10.1038/s41537-026-00806-2

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00806-2

Keywords: schizophrenia, MCTP2, negative symptoms, pharmacogenomics, GWAS, aripiprazole, ziprasidone, PANSS, calcium signaling, synaptic proteins, eQTL, cognitive function

The research, conducted by Hengyi Cao of the Feinstein Institutes for Medical Research and Zucker Hillside Hospital and Oliver Y. Chén of Lausanne University Hospital and the University of Lausanne, drew on data from the Human Connectome Project for Early Psychosis, a large-scale neuroimaging initiative designed to capture the brain in the earliest stages of psychotic illness. The analysis included 100 patients with early psychosis and 49 healthy controls. Rather than asking a single question about whether poverty is associated with schizophrenia, the team built a statistical model of a chain of events, testing whether parental socioeconomic status shapes the functional connectivity of the cerebellum, whether that connectivity in turn supports verbal cognitive ability, and whether verbal ability ultimately buffers or fails to buffer the severity of alogia, the poverty-of-speech symptom that belongs to the negative dimension of psychosis.

The choice of the cerebellum as a way station in this chain reflects a quiet revolution in neuroscience. For most of the twentieth century, the cerebellum, the densely folded structure tucked beneath the occipital lobes, was understood almost exclusively as a calibrator of movement, the place where motor commands were fine-tuned and smoothed. That view has been steadily dismantled by converging evidence from lesion studies, functional imaging, and connectivity mapping showing that cerebellar regions engaged in motor control are anatomically separate from regions that communicate with the association cortices governing language, working memory, and abstract thought. In schizophrenia, abnormalities in these cerebellar-frontoparietal circuits have repeatedly been linked to cognitive impairment, and Cao’s own earlier work had found that verbal ability fully mediated the relationship between cerebellar-frontoparietal connectivity and alogia severity. What remained unknown was what stood upstream of that circuit: what determines, in the first place, how well a person’s cerebellum talks to their frontal and parietal cortex.

The new study’s answer centers on parental socioeconomic status, a composite demographic marker of the family environment in which a patient grew up. Socioeconomic disadvantage is among the most consistently documented environmental risk factors for psychotic disorders, and it is also known to shape brain development broadly, influencing everything from cortical thickness to the integrity of white matter tracts. But the field has struggled to connect those two observations mechanistically. Disadvantage is associated with higher rates of psychosis, and brains of people with psychosis differ from those of controls, but the intermediate steps, the actual biological and psychological conduits through which early environment becomes later symptom, have largely been inferred rather than demonstrated in a single statistical framework.

To build that framework, the researchers first used linear regression models to estimate how parental SES related to cerebellar connectivity and to verbal ability, running the estimates separately in patients and in healthy controls. The comparison between groups proved critical. A significant group-by-SES interaction emerged for cerebellar connectivity, with a p-value of 0.003, meaning that the relationship between family background and cerebellar circuitry was statistically different in patients than in controls. For verbal ability, the interaction fell just short of conventional significance at p = 0.055, a borderline result the authors report transparently. When the groups were examined individually, the pattern became sharper: in patients, both cerebellar connectivity and verbal ability were significantly associated with parental SES, with p-values below 0.001, while in healthy controls neither association reached significance.

That asymmetry is the study’s most intriguing finding. It suggests that the same demographic variable, parental socioeconomic status, is inert with respect to these particular brain and cognitive measures in people without psychosis, yet powerfully coupled to them in people with the illness. One way to read this is through the lens of vulnerability: perhaps early-life disadvantage leaves its mark on cerebellar-frontoparietal circuits in everyone, but only in individuals already susceptible to psychosis does that mark translate into measurable disruption of the circuit and, downstream, of the verbal cognition that depends on it. Alternatively, the patient-specific coupling could reflect a cascade in which genetic and environmental risks converge, so that SES functions not as a universal sculptor of the cerebellum but as a stressor whose consequences are unmasked in a vulnerable nervous system. The cross-sectional design of the study cannot adjudicate between these readings, and the authors are careful not to overclaim causality from a single time point.

The centerpiece of the analysis, however, was the structural equation model, a statistical technique that allows researchers to test whether an entire hypothesized chain of effects fits the observed data better than competing alternatives. Rather than examining each link in isolation, structural equation modeling evaluates the pathway as a whole, estimating both the direct and indirect effects that flow through each intermediate variable. The serial model the team tested proposed a specific sequence: parental SES influencing cerebellar connectivity, cerebellar connectivity influencing verbal ability, and verbal ability influencing alogia severity. The data supported it. A significant serial mediation effect was detected, with a p-value of 0.008, indicating that the combined route from family background through cerebellar circuitry and verbal cognition to poverty of speech was unlikely to have arisen by chance.

In practical terms, the pathway implies a hierarchy of risk. A child raised in a household with fewer socioeconomic resources is, in this model, more likely to arrive at adolescence with atypical functional coupling between the cerebellum and the frontoparietal networks that support language. That atypical coupling is associated with weaker verbal ability, the cognitive machinery of word retrieval, sentence construction, and fluent expression. And weakened verbal ability is associated with more severe alogia, the symptom in which speech becomes sparse, empty, and slow. Each link in the chain is a measurable quantity, and the model quantifies how much of the association between parental SES and alogia travels through the two intermediate stations rather than directly. The finding that the mediation is serial, rather than parallel, matters because it imposes an order on the biology: the cerebellar circuit sits upstream of cognition, and cognition sits upstream of the symptom, which is precisely the architecture one would expect if the cerebellum contributes to higher cognition through its interactions with cortical networks rather than acting on symptoms directly.

The implications reach in two directions at once. Scientifically, the study strengthens the case that the cerebellum deserves a central place in models of psychosis, not as an incidental finding on brain scans but as a node whose connectivity carries information about both developmental environment and current symptomatology. It also illustrates a broader principle gaining traction in psychiatry: that demographic risk factors such as socioeconomic status are not merely correlates of mental illness to be statistically controlled away, but variables that may exert their influence through specific, identifiable neural mechanisms. Clinically, the pathway suggests possible points of intervention. If verbal ability is the final cognitive gateway through which cerebellar dysconnectivity expresses itself as alogia, then language-focused cognitive remediation, speech and language therapy, or interventions that target the circuitry of the cerebellar-frontoparietal network might each interrupt the cascade at a different point. The authors’ work was supported by NIH grants R01MH138682 and R01MH137501 and an Alkermes Pathways Research Award, and the study is open access, allowing other teams to scrutinize and extend the model.

Important caveats temper the excitement. The sample, while drawn from a rigorously curated dataset, comprises 100 patients and 49 controls, and mediation analyses of this kind are sensitive to sample size, measurement reliability, and model specification. Parental SES was measured retrospectively as a demographic variable, and the study cannot disentangle genetic confounding, since parents pass on both their environments and their genes. The borderline interaction for verbal ability leaves open the possibility that the cognitive link is less robust than the neural one. And because the data are cross-sectional, the serial order of the pathway, however biologically plausible, remains a hypothesis about sequence rather than a demonstration of it. Longitudinal studies that follow young people at familial high risk, tracking SES, cerebellar connectivity, and language development before illness onset, would be needed to confirm that the chain unfolds in time as the model proposes. Even so, the study offers something the field has lacked: a single, statistically coherent narrative connecting a social determinant of health, a specific brain circuit, a specific cognitive faculty, and a specific symptom, each measured and each linked to the next. In a discipline where social factors and neurobiology have too often lived in separate literatures, that integration is itself a finding worth attending to.

Subject of Research: The serial mediation pathway linking parental socioeconomic status, cerebellar connectivity, verbal cognition, and alogia in psychosis

Article Title: A serial mediation pathway linking parental socioeconomic status, cerebellar connectivity, verbal cognition, and alogia in psychosis

Article References: Cao, H., & Chén, O. Y. (2026). A serial mediation pathway linking parental socioeconomic status, cerebellar connectivity, verbal cognition, and alogia in psychosis. Schizophrenia. https://doi.org/10.1038/s41537-026-00803-5

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00803-5

Keywords: psychosis, schizophrenia, socioeconomic status, cerebellum, brain connectivity, verbal cognition, alogia, negative symptoms, structural equation modeling, Human Connectome Project for Early Psychosis, neuroimaging, cognitive deficits

The research, led by Giulia Cattarinussi and Fabio Sambataro of the University of Padova and King’s College London, together with senior author Paola Dazzan and a broad consortium of UK investigators, focused on the striatum, a cluster of deep brain structures that includes the nucleus accumbens and the pallidum. The striatum sits at the heart of fronto-striatal circuits, the loops of communication that connect the basal ganglia to the frontal lobes and that are known to be involved in motivation, reward processing, and cognitive control. Disturbances in these circuits have repeatedly been implicated in schizophrenia, particularly in the negative symptoms of the illness, such as social withdrawal, blunted emotion, and loss of drive, which often respond poorly to existing antipsychotic medications.

To probe the relationship between inflammation and these circuits, the team turned to data from the BeneMin trial, a Medical Research Council-funded study that tested whether the antibiotic minocycline, chosen for its anti-inflammatory properties, could improve negative symptoms in recent-onset schizophrenia. From this trial, the researchers assembled a cohort of 132 individuals with first-episode schizophrenia who had undergone resting-state functional MRI, a technique that maps spontaneous, synchronized activity across the brain while participants simply lie still in the scanner. Because the participants were scanned early in the course of their illness, the study offered a rare window into the biology of schizophrenia before years of illness chronicity, medication exposure, and lifestyle factors could muddy the picture.

A central methodological strength of the study lay in how the researchers defined inflammation. Rather than simply measuring a single inflammatory marker, they applied a previously established semi-supervised machine learning clustering solution that integrates patterns of inflammatory measures to assign each participant to an inflammation group. At baseline, individuals classified into the elevated C-reactive protein group, or High-CRP group, were compared with those in a low-inflammation group. C-reactive protein, or CRP, is a protein produced by the liver in response to inflammatory signaling and is widely used in clinical medicine as a sensitive gauge of systemic inflammation. The clustering approach, having been derived from earlier work, allowed the team to stratify patients in a data-driven way rather than relying on arbitrary cutoffs alone.

The seed-based functional connectivity analysis then asked a straightforward question: do the striatal regions of inflamed and non-inflamed patients talk to the rest of the brain in the same way? The answer was no. At baseline, individuals in the High-CRP group showed significantly higher functional connectivity between the right nucleus accumbens and the left middle frontal gyrus, and between the right pallidum and the left middle frontal gyrus extending into the precentral gyrus, compared with their low-inflammation counterparts. In other words, in patients with elevated peripheral inflammation, the reward-related and motor-related portions of the striatum were more strongly synchronized with regions of the frontal cortex that govern planning, executive control, and movement.

When the researchers repeated the analysis at twelve-month follow-up, the same pattern of heightened fronto-striatal connectivity was still visible in the High-CRP group, although the differences no longer reached statistical significance. This persistence across a year of illness suggests that the inflammatory signature is not a fleeting artifact of an acute psychotic episode but may reflect a more stable biological subgroup within schizophrenia. The authors interpret this greater fronto-striatal connectivity as a distinct neural signature associated with greater inflammation, one that is present from the very beginning of the disorder.

Perhaps the most clinically provocative finding emerged when the researchers connected the imaging results to symptoms. The strength of functional connectivity between the right nucleus accumbens and the left superior and middle frontal gyri correlated with scores on the negative symptom subscale of the Positive and Negative Syndrome Scale, the standard clinical instrument for measuring psychosis severity. Crucially, this correlation was significantly stronger in the High-CRP group than in the low-inflammation group. This means that in patients with elevated inflammation, the degree of fronto-striatal over-connection tracked the severity of the very symptoms, such as apathy and social withdrawal, that most often keep people with schizophrenia from returning to work, study, and relationships.

The cognitive dimension of the study told a more nuanced story. The researchers used the Digit Symbol Substitution Test, a rapid measure of processing speed and attention, as a proxy for cognitive function, but the headline association centered on negative symptoms rather than cognition. This distinction matters, because negative symptoms and cognitive impairment, while often intertwined, are thought to arise from partly separable neural mechanisms, and treatments that target one may not necessarily rescue the other. The present results suggest that inflammation-related alterations in striatal connectivity are more tightly bound to the motivational and affective dimensions of the illness than to its cognitive toll, at least in the early phase.

Why would peripheral inflammation leave its fingerprint on brain circuits at all? Several mechanisms, well established in the broader neuroscience literature, offer plausible routes. Inflammatory cytokines circulating in the blood can signal to the brain through the vagus nerve, through leaky regions of the blood-brain barrier, and through endothelial and glial activation pathways. Once inflammatory signaling reaches the brain, it can alter neurotransmitter metabolism, including the kynurenine pathway of tryptophan degradation and dopamine synthesis, and it can disrupt the synaptic plasticity that underlies coordinated network activity. The striatum, densely innervated by dopaminergic fibers and exquisitely sensitive to immune signaling, is a plausible junction where systemic inflammation could translate into altered circuit dynamics. The observation of increased, rather than decreased, connectivity in the inflamed subgroup is consistent with the idea that inflammation may induce compensatory or maladaptive strengthening of particular fronto-striatal loops rather than a uniform dampening of brain communication.

The clinical implications are considerable. If a subgroup of people with first-episode schizophrenia carries a high-inflammation biological profile with a characteristic connectivity signature, then inflammation itself becomes a potential treatment target. The authors suggest that interventions aimed at reducing inflammation may represent novel strategies for modulating striatal connectivity and ameliorating negative symptoms. The BeneMin trial from which these data derive was, after all, designed to test minocycline for exactly that purpose, and the present findings provide a mechanistic framework for why such approaches might work in some patients and not others. Precision psychiatry, in which biomarkers such as CRP and machine-learned inflammatory profiles guide the selection of anti-inflammatory add-on treatments, moves a step closer to practical reality with results like these.

Important caveats remain. The study is observational in its core analysis, so it cannot determine whether inflammation drives the connectivity differences, whether altered brain activity drives inflammation, or whether both reflect a third underlying process. The follow-up connectivity differences, while directionally consistent, did not reach statistical significance, and the cognitive measure did not show the same group-specific associations as the symptom measures. Replication in independent cohorts and direct tests of whether reducing inflammation normalizes fronto-striatal connectivity will be essential. Even so, by anchoring the inflammation hypothesis of schizophrenia in concrete circuit-level evidence from the earliest stage of illness, the study sharpens a question that psychiatry has been circling for decades: for a substantial subgroup of patients, schizophrenia may be, in part, an inflammatory disorder of the brain, and recognizing that early could change how the illness is detected, stratified, and treated.

Subject of Research: The relationship between peripheral inflammation and striatal functional connectivity in first-episode schizophrenia

Article Title: Neural correlates of peripheral inflammation in individuals with first-episode schizophrenia

Article References: Cattarinussi, G., Sambataro, F., Lalousis, P. A., Suckling, J., Barnes, T. R. E., Byrne, K., Chaudhry, I. B., Drake, R. J., Giordano, A., Husain, N., Jones, P. B., Joyce, E., Knox, E., Krynicki, C., Lawrie, S. M., Lewis, S., Lisiecka-Ford, D. M., Nikkheslat, N., Pariante, C. M., … Dazzan, P. (2026). Neural correlates of peripheral inflammation in individuals with first-episode schizophrenia. Schizophrenia. https://doi.org/10.1038/s41537-026-00811-5

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00811-5

Keywords: schizophrenia, first-episode psychosis, inflammation, C-reactive protein, functional MRI, striatum, nucleus accumbens, fronto-striatal connectivity, negative symptoms, machine learning, neuroimmunology, BeneMin trial

The research, led by Lukas Roell of the University of Melbourne and LMU Munich together with colleagues across Australia, Germany and Brazil, addresses one of the most stubborn gaps in modern psychiatry. Psychotic disorders such as schizophrenia still lack treatment-informative biomarkers, and this deficit is most consequential during the earliest stages of illness, when interventions are thought to be most effective. Clinicians can identify people at clinical high risk for psychosis using structured interviews that detect attenuated, subthreshold psychotic symptoms, but the field has struggled to predict which of these individuals will deteriorate, which will recover, and which will develop full-blown psychosis. A reliable neural marker could transform that uncertainty into actionable risk stratification.

To hunt for such a marker, the team turned to the North American Prodrome Longitudinal Study, known as NAPLS-3, a multicenter observational cohort that has followed young people at clinical high risk for psychosis with repeated clinical assessments and magnetic resonance imaging. The analysis drew on longitudinal clinical and functional neuroimaging data from 434 participants, comprising 356 individuals at clinical high risk and 78 healthy controls, collected across an eight-month period. Rather than taking a single snapshot, the investigators modeled how connectivity changed over time within each participant and how those changes related to the parallel evolution of symptoms and functioning, using latent variable regression models that can accommodate measurement error in both the imaging and clinical variables.

The target of the analysis was not the hippocampus’s famous long-range connections to cortical networks, but its internal wiring. Functional connectivity measured with resting-state functional MRI reflects the statistical synchronization of activity between brain regions, and the hippocampus, despite its small size, is organized along its long axis into anterior, intermediate and posterior segments with distinct connectivity profiles. By examining connectivity within the hippocampus itself, the researchers sought to integrate two influential strands of etiological theory: one pointing to hippocampal pathology as a core feature of schizophrenia, and the other, the dysconnection hypothesis, framing psychotic disorders as disorders of neural communication rather than of isolated brain regions.

The results were strikingly specific. Decreases in intrahippocampal connectivity over the eight-month window tracked worsening negative symptoms, the amotivational and socially withdrawn features of the psychosis spectrum that are notoriously difficult to treat, as well as worsening depressive symptoms and declining psychosocial functioning. The same relationship did not hold for attenuated positive symptoms, such as unusual thoughts or perceptual disturbances, nor for cognition. The pattern was also specific to the high-risk group: healthy controls showed no comparable link, and the association did not emerge when the researchers examined connectivity within other brain areas. In other words, this was not a generic signature of scanning noise or of general distress, but a localized, diagnostically relevant signal.

Perhaps the most consequential finding concerns the direction of time. By modeling the temporal sequence of the associations, the team found that an early decrease in connectivity within the hippocampus preceded a subsequent worsening of negative symptoms, rather than the other way around. This ordering matters enormously for interpretation. If symptoms had predicted the connectivity decline, the brain change could simply be a downstream consequence of illness behavior, such as social withdrawal or poor sleep. Because the neural change came first, it is a credible candidate for a predictive marker, one that could flag deteriorating trajectories before they become clinically obvious and before opportunities for early intervention have slipped away.

Yet the study also delivers a sobering caveat. Intrahippocampal connectivity decline did not predict transition to psychosis, the outcome that has historically dominated research on the clinical high-risk state. This null result reframes what the marker is actually for. Most young people identified as high risk never develop psychosis, but many still experience significant affective and functional difficulties, and recent meta-analytic work has emphasized the transdiagnostic burden carried by this population, including high rates of comorbid depression and anxiety. The new findings suggest that hippocampal connectivity is less a crystal ball for psychotic conversion than a barometer of the affective-motivational and functional trajectories that shape quality of life regardless of whether psychosis ever emerges.

The specificity of the signal also fits a growing body of evidence implicating the hippocampus in the earliest phases of psychotic illness. Prior studies have documented resting hyperperfusion of the hippocampus in people at ultra-high risk, aberrant interactions between hippocampal activity and striatal dopamine in clinical high-risk individuals, and postmortem evidence of reduced hippocampal neuron density and oligodendrocyte numbers in schizophrenia. The hippocampus sits at the nexus of risk and resilience for the disorder, and its internal circuitry, organized along a long axis with functionally differentiated subregions, offers a plausible substrate for the motivational and affective disturbances captured by negative symptom ratings. The new study extends this literature by showing that the relevant signal is longitudinal, internal to the structure, and temporally predictive.

Methodologically, the work leans on the scale and rigor of NAPLS-3, whose methods and baseline description were published in 2022, and on modern neuroimaging pipelines, including the fMRIPrep preprocessing workflow and parcellation schemes derived from the Human Brainnetome Atlas. The authors made their analysis code publicly available on GitHub, and the underlying data are accessible through the NIMH Data Archive, subject to data access permissions. These choices matter because functional connectivity measures have historically been criticized for modest test-retest reliability, and longitudinal designs that track within-person change over months place heavy demands on measurement stability. Replication across independent cohorts, and eventually within individuals using precision functional mapping, will be essential before the marker can move into clinical use.

The translational horizon is already visible. The authors suggest that early reductions in intrahippocampal connectivity may help stratify at-risk individuals according to their expected affective and functional outcomes, and they point to neurostimulation as a potential intervention target, noting emerging work on lesion-derived psychosis circuits and on holographic transcranial ultrasound neuromodulation capable of recruiting distributed brain circuits. Large-scale efforts such as the Accelerating Medicines Partnership schizophrenia cohort study are simultaneously building the infrastructure for biomarker-driven care in the high-risk state. If the findings hold, a clinician seeing an anxious, withdrawn teenager with attenuated psychotic symptoms might one day order a resting-state scan, and a decline in the hippocampus’s internal dialogue could tip the balance toward earlier, more targeted support, long before the most damaging symptoms take hold.

Subject of Research: Intrahippocampal functional connectivity as a longitudinal neuroimaging marker of early clinical trajectories in the psychosis risk state

Article Title: Connectivity within the hippocampus as a neural marker of early clinical trajectories in the psychosis risk state

Article References: Roell, L., Lindner, C., Tian, Y. E., Chopra, S., Maurus, I., Moussiopoulou, J., Yakimov, V., Korman, M., Keeser, D., Schmitt, A., Falkai, P., Di Biase, M. A., Zitzmann, S., & Zalesky, A. (2026). Connectivity within the hippocampus as a neural marker of early clinical trajectories in the psychosis risk state. Nature Mental Health. https://doi.org/10.1038/s44220-026-00739-w

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00739-w

Keywords: hippocampus, psychosis risk, clinical high risk, functional connectivity, negative symptoms, NAPLS-3, biomarker, schizophrenia, neuroimaging, depression, early intervention, neurostimulation

Negative symptoms represent one of the most challenging dimensions of schizophrenia. Unlike positive symptoms such as hallucinations and delusions, which involve the presence of abnormal experiences, negative symptoms involve the absence or diminution of normal functioning. These include avolition, or a reduced drive to initiate and sustain goal-directed activity, anhedonia, or a diminished capacity to experience pleasure, asociality, blunted affect, and poverty of speech. For many patients, these symptoms persist even when antipsychotic medications successfully control hallucinations and delusions, and they are strongly linked to social isolation, unemployment, and reduced quality of life.

The scarcity of effective treatments for negative symptoms has long frustrated clinicians and researchers. Most antipsychotic drugs, which primarily act on dopamine systems to suppress positive symptoms, offer little benefit for motivational and pleasure deficits. Psychosocial approaches such as cognitive behavioral therapy and social skills training can help, but their effects are often modest, and access to trained therapists remains a barrier in many health systems. This treatment gap has made the development of scalable, evidence-based interventions for negative symptoms a major priority in mental health research.

CT-155 was developed as a digital therapeutic, a class of software-based interventions intended to deliver therapeutic benefit through structured engagement, often on a computer or tablet. Digital therapeutics differ from general wellness apps in that they are designed to be evaluated in clinical trials with the same rigor expected of medical treatments, measuring safety and efficacy against defined endpoints. In this trial, the intervention was tested specifically against motivation and pleasure negative symptoms, the domain that most directly shapes a patient’s ability to pursue goals, enjoy daily activities, and maintain social connections.

The randomized clinical trial design is the gold standard for determining whether an intervention produces genuine benefit beyond placebo effects or the natural course of a condition. By randomly assigning participants to receive either the digital therapeutic or a comparator, researchers can isolate the specific contribution of the active intervention. In this study, the trial demonstrated that CT-155 improved motivation and pleasure negative symptoms to a degree the investigators characterized as small to moderate. While such effect sizes may sound modest, in psychiatry they are consistent with the magnitude of benefit typically observed for approved psychosocial interventions and pharmacologic treatments, which underscores the clinical relevance of the finding.

Safety and tolerability are equally critical considerations for any new schizophrenia treatment, particularly because patients often take multiple medications and may be sensitive to side effects. The trial reported that CT-155 was well tolerated and safe, an outcome that is notable for a software-based intervention that does not add pharmacologic burden. Because the therapy works through structured digital engagement rather than drug action on brain chemistry, it can in principle be combined with existing antipsychotic regimens without concerns about drug-drug interactions, supporting its proposed role as an adjunctive therapy rather than a replacement for medication.

The corresponding author of the study is Abhishek Pratap, PhD, of Global Clinical Development Mental Health and Eye Health at Boehringer Ingelheim Pharmaceuticals Inc, indicating that the intervention emerged from an industrial research and development program focused on mental health. The involvement of a major pharmaceutical company reflects a broader trend in which drug developers are expanding into digital and combination approaches, recognizing that software-delivered interventions can address aspects of psychiatric illness that molecules alone have failed to reach.

Perhaps the most consequential implication of the finding is scalability. Traditional psychosocial interventions for schizophrenia require trained clinicians, scheduled sessions, and institutional infrastructure, all of which limit how many patients can be reached. A digital therapeutic, once validated and deployed, can in principle be distributed widely and used with far fewer constraints on clinician time and geography. The authors suggest that CT-155 may represent a scalable, accessible option for improving schizophrenia negative symptoms, a claim that carries significant weight for health systems struggling to meet the demand for mental health care.

At the same time, the small-to-moderate effect size is a reminder that digital therapeutics are not a cure and that real-world performance can differ from trial conditions. Questions about long-term durability of benefit, adherence over months and years of use, and effectiveness across diverse patient populations will shape how such interventions are ultimately integrated into care. Digital interventions also depend on patients engaging with the software, and motivation is precisely the faculty impaired by negative symptoms, a challenge that the design of the therapy must address for sustained benefit.

Nevertheless, the trial marks a meaningful step forward in a field where genuine treatment advances for negative symptoms have been rare. Published in JAMA Network Open, a peer-reviewed journal, the study adds to a growing body of evidence that carefully engineered digital interventions can produce clinically measurable improvements in serious mental illness. For the millions of people worldwide living with schizophrenia, many of whom face persistent motivational and pleasure deficits that medications do not relieve, a safe, well-tolerated, and scalable adjunctive therapy offers a reason for cautious optimism and a signal of where psychiatric treatment may be heading.

Subject of Research: A randomized clinical trial of the digital therapeutic CT-155 for negative symptoms of schizophrenia

Article Title: A digital therapeutic intervention for negative symptoms of schizophrenia

Article References: A digital therapeutic intervention for negative symptoms of schizophrenia. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: schizophrenia, negative symptoms, digital therapeutics, CT-155, randomized clinical trial, JAMA Network Open, motivation and pleasure deficits, psychiatry, mental health, Boehringer Ingelheim, adjunctive therapy, avolition

For decades, clinicians and researchers have grouped the heterogeneous experiences of schizophrenia into broad domains. Positive symptoms such as hallucinations and delusions were separated from negative symptoms like blunted affect and social withdrawal, while disorganized speech and behavior formed a third cluster. These divisions, formalized in instruments such as the Positive and Negative Syndrome Scale, shaped drug development trials, genetic association studies, and the diagnostic criteria in the DSM and ICD. Yet the assumption that these categories reflect distinct underlying biological mechanisms has never been firmly established, and critics have argued that the dimensions are artifacts of the measurement instruments rather than discoveries about the illness itself.

Graph analysis, the approach at the heart of the new study, treats symptoms as nodes in a network and statistical associations between them as edges. Instead of asking whether a set of preassigned items load onto a particular factor, exploratory graph analysis applies algorithms derived from network science to detect communities of tightly interconnected symptoms. Methods such as the walktrap algorithm combined with regularization techniques can identify clusters that emerge purely from the pattern of relationships in the data. Researchers can then compare these data-driven communities against the conventional dimensions to see whether the traditional structure holds up under scrutiny.

The appeal of this methodology lies in its ability to sidestep some of the assumptions baked into classical factor analysis. Exploratory graph analysis has been shown in simulation studies to recover the correct number of dimensions more reliably than older techniques, particularly when samples are moderate in size or when the underlying factors are correlated. In psychometrics more broadly, the technique has spread rapidly, finding applications in depression, personality research, and quality-of-life measurement. Its arrival in schizophrenia research signals a broader shift toward network approaches that view mental disorders as systems of interacting elements rather than reflections of single latent causes.

Applying these tools to symptom ratings from people with schizophrenia, the researchers examined whether positive, negative, and disorganized symptoms genuinely form separable communities, or whether alternative configurations better describe the clinical reality. The stakes of this question are considerable. If symptom dimensions overlap more than assumed, clinical trials that measure only one domain may miss treatment effects that ripple across the network. If, on the other hand, the dimensions are robust, they remain valid targets for precision psychiatry approaches that aim to match patients to treatments based on symptom profiles rather than categorical diagnoses.

The study also speaks to a persistent puzzle in schizophrenia genetics. Genome-wide association studies have identified hundreds of genetic variants that contribute to risk, but connecting those variants to specific symptom dimensions has proven difficult, with studies of symptom genetics often yielding inconsistent results. Part of the inconsistency may stem from measurement: if the dimensions themselves are unstable across cohorts, instruments, and statistical methods, then genetic analyses built on top of them inherit that instability. Establishing whether the classical structure is reproducible under modern, assumption-light methods is therefore a prerequisite for meaningful biological discovery.

Network perspectives bring additional conceptual benefits. They make it possible to identify bridge symptoms, items that connect otherwise separate communities and may act as pathways through which dysfunction spreads. In depression research, for example, bridge symptoms such as sleep disturbance have been proposed as links between anxiety and mood clusters. In schizophrenia, identifying which symptoms bridge positive and negative domains could point to intervention targets with the broadest downstream impact, and could help explain why some patients deteriorate along multiple dimensions simultaneously while others remain relatively circumscribed in their difficulties.

The methodological rigor demanded by graph analysis is also part of the story. Exploratory graph analysis relies on estimating a regularized partial correlation network, typically through the graphical least absolute shrinkage and selection operator, which sets small spurious associations to zero and leaves a sparse network whose community structure can be extracted. Stability checks, such as bootstrapped estimates of edge weights and centrality indices, are essential to ensure that the detected communities are not statistical mirages. Cross-validation across independent samples provides a further safeguard, and the field has increasingly insisted on such replication before accepting any new dimensional structure as credible.

What makes this study timely is the convergence of several trends in psychiatric science. The National Institute of Mental Health’s Research Domain Criteria initiative has pressed researchers to move beyond diagnostic categories toward dimensions grounded in behavior and biology. Meanwhile, large-scale datasets and improved computational tools have made it feasible to test the architecture of psychopathology with unprecedented statistical power. Revisiting the symptom dimensions of schizophrenia with contemporary network methods is a natural next step in this program, and the findings carry implications that extend from the clinic to the genetics laboratory.

For clinicians, the message is that the familiar dimensional map of schizophrenia remains a useful, but not infallible, guide. For researchers, the study demonstrates that the tools of network science can interrogate long-standing psychiatric constructs in ways that classical psychometrics could not, potentially revealing where the traditional categories deserve preservation and where they require revision. As the field moves toward biologically informed classification, studies of this kind serve as a bridge, testing whether the clinical vocabulary accumulated over a century of observation can withstand the scrutiny of modern data science, and helping to ensure that future research into the causes and treatments of schizophrenia rests on foundations that can bear the weight.

Subject of Research: Symptom dimensions in schizophrenia analyzed with exploratory graph analysis

Article Title: Revisiting symptom dimensions in schizophrenia with exploratory graph analysis

Article References: Illing, S., & Leucht, S. (2026). Revisiting symptom dimensions in schizophrenia with exploratory graph analysis. Schizophrenia, 12(1), Article 72. https://doi.org/10.1038/s41537-026-00799-y

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00799-y

Keywords: schizophrenia, symptom dimensions, exploratory graph analysis, network analysis, psychometrics, positive symptoms, negative symptoms, disorganization, precision psychiatry, psychiatric classification, statistical methods, mental health

Schizophrenia affects roughly one in every hundred people worldwide, and while antipsychotic medications control many of its features, a substantial fraction of patients continue to experience persistent auditory hallucinations, hearing voices that no one else can hear, as well as entrenched negative symptoms such as social withdrawal, emotional flatness, and loss of drive. These residual symptoms are among the most disabling aspects of the illness and are notoriously resistant to pharmacological escalation. This therapeutic gap has fueled decades of interest in brain stimulation techniques that might modulate the dysfunctional neural circuits thought to underlie them, offering hope for patients who have exhausted conventional options.

The technique tested in STIM’Zo belongs to a family of methods known as low-intensity transcranial electrical stimulation. Unlike transcranial magnetic stimulation, which uses rapidly changing magnetic fields to induce currents strong enough to trigger neuronal firing, transcranial electrical stimulation delivers currents so weak, typically on the order of one to two milliamps, that they do not directly cause neurons to discharge. Instead, these faint currents subtly shift the resting electrical potential of cortical neurons, nudging their excitability up or down depending on the stimulation protocol. Transcranial direct current stimulation applies a steady current, whereas tRNS delivers current that fluctuates randomly across a range of frequencies, a design intended to prevent the brain from habituating to a constant signal and to exploit the tendency of neural networks to resonate with stochastic input.

Earlier evidence for tRNS and its close cousin tDCS in schizophrenia rested on a fragile foundation of case reports and small pilot studies, some of which reported striking reductions in hallucination severity. Encouraged by these signals, the STIM’Zo investigators, led by Jerome Brunelin, Marine Mondino, and Emmanuel Poulet and their collaborators, designed a definitive test. The trial was registered as NCT02744989 and received support from the French Ministry of Health, the NeuroDis foundation, and the Centre Scientifique de Monaco, with no funder involvement in the design, analysis, or reporting of the study.

The trial’s methodology reflects the highest standard of clinical rigor. Triple-blind means that patients, the clinicians assessing outcomes, and the statisticians analyzing the data all remained unaware of who received active stimulation and who received sham. The sham condition was engineered to mimic the sensations of real stimulation, typically a brief tingling or itching at the electrode sites at the start of each session, without delivering therapeutic current. Patients were randomized across multiple centers, and the primary outcome was defined in advance as clinical response at Day 5, operationalized as a reduction of at least 25 percent on the total score of the Positive and Negative Syndrome Scale, the most widely used standardized instrument for measuring schizophrenia symptom severity. Secondary outcomes tracked symptoms at one, three, and six months using additional instruments including the Auditory Hallucinations Rating Scale, the Calgary Depression Scale for Schizophrenia, the Clinical Global Impression scale, and a schizophrenia-specific quality of life questionnaire.

The primary analysis included 132 patients, 64 in the active stimulation group and 68 in the sham group, with balanced sex distributions across arms. The result was unambiguous. At Day 5, only 6 of 64 patients in the active group, or 9.4 percent, met the response criterion, compared with 9 of 68 patients, or 13.2 percent, in the sham group. The difference between groups was not statistically significant, with an effect estimate of negative 0.38 and a 95 percent confidence interval spanning negative 1.64 to 0.89, and a p value of 0.56. In plain terms, the sham procedure performed slightly, though not significantly, better than the real intervention. None of the secondary outcomes, measured over the following six months, showed significant differences either, meaning the stimulation neither reduced hallucinations, nor improved negative symptoms, nor lifted mood or quality of life beyond what the placebo ritual itself achieved.

Safety, at least, was not in question. Serious adverse events unrelated to treatment occurred in five patients in the active group and seven in the sham group, a difference that was not statistically significant. The technique was well tolerated, and the trial confirmed that low-intensity electrical stimulation of this kind carries no meaningful physical risk when properly administered. But safety without efficacy is a hollow consolation for patients and clinicians, and the authors’ conclusion was blunt: tRNS did not show superiority over sham in reducing persistent symptoms of schizophrenia.

Why did a technique that showed promise in early studies fail so decisively here? The most instructive answer lies in the trial design itself. Small pilot studies and case reports are exquisitely vulnerable to placebo effects, publication bias, and regression to the mean, and psychiatric symptoms are especially susceptible to the powerful psychological ritual of receiving what feels like an active treatment. The sham group’s 13.2 percent response rate illustrates how much apparent improvement can arise from expectation, attention, and the natural fluctuation of symptoms alone. When these factors are rigorously controlled, as they were in STIM’Zo, the true effect of the intervention can shrink dramatically or vanish. The trial also raises deeper questions about mechanism: whether currents this weak, applied over the scalp and attenuated by skull and skin, can reach and meaningfully alter the deep and distributed circuits implicated in hallucinations remains uncertain. Some researchers argue that stimulation parameters, electrode positioning over regions such as the temporoparietal junction and dorsolateral prefrontal cortex, or the duration of treatment may need optimization, but the STIM’Zo data provide no support for the technique in its current form.

The implications extend well beyond tRNS. The result tempers enthusiasm for a wave of consumer and clinical enthusiasm around electrical brain stimulation for psychiatric conditions, and it underscores the necessity of large, triple-blind, sham-controlled trials before any brain stimulation protocol is adopted into routine care. It also offers a model of how the field should proceed: preregistered endpoints, multicenter recruitment, transparent funding, and honest reporting of negative results. For the patients who participated, and for the millions living with persistent voices and blunted lives, the trial did not deliver a new therapy, but it delivered something arguably just as valuable, a clear and trustworthy answer that redirects research toward approaches with a genuine chance of working. In science, knowing what does not work, and knowing it with confidence, is the first step toward finding what does.

Subject of Research: A triple-blind randomized trial testing transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia.

Article Title: Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo)

Article References: Brunelin, J., Mondino, M., Plaze, M., Attal, J., Benoit, M., El-Hage, W., Galvao, F., Haesebaert, J., Jardri, R., Llorca, P. M., Magaud, L., Nathou, C., Szekely, D., Fakra, E., & Poulet, E. (2026). Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo). BMC Medicine. https://doi.org/10.1186/s12916-026-05227-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05227-7

Keywords: schizophrenia, tRNS, brain stimulation, auditory hallucinations, negative symptoms, placebo-controlled trial, BMC Medicine, psychiatry, tDCS, clinical trial, PANSS, noninvasive stimulation